Related Experiment Videos
Clinical experience with drug-eluting stents
1Department of Medicine, (Knight Cardiac Catheterization Laboratory, Cardiovascular Division, Massachusetts General Hospital) Harvard Medical School, Boston, Massachusetts, USA.
Reviews in Cardiovascular Medicine
|December 13, 2002
Summary
Drug-eluting stents offer a promising solution to in-stent restenosis after coronary intervention. Clinical trials show sirolimus and paclitaxel significantly reduce restenosis rates, improving procedural success.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Biomaterials Science
Background:
- In-stent restenosis remains a significant challenge in coronary intervention, affecting 10-50% of patients.
- Existing catheter and stent technologies have limitations in preventing restenosis.
- Novel therapeutic strategies are needed to improve long-term outcomes.
Purpose of the Study:
- To evaluate the clinical utility of drug-eluting stents (DES) for preventing in-stent restenosis.
- To review the current clinical experience with DES in coronary interventions.
- To explore the future potential of DES in clinical practice.
Main Methods:
- Examination of clinical trial data for novel antirestenotic agents.
- Focus on drug delivery systems integrated with coronary stents.
- Analysis of sirolimus- and paclitaxel-eluting stents.
Main Results:
- Drug-eluting stents demonstrate significant reductions in restenosis rates.
- Novel antirestenotic agents delivered locally from stents show high efficacy.
- Breakthroughs in polymer science enable effective local drug delivery.
Conclusions:
- Drug-eluting stents represent a major advancement in managing in-stent restenosis.
- Sirolimus and paclitaxel show remarkable efficacy in clinical trials.
- Further examination of clinical experience will guide the future use of DES.